We are live on ! Find out more
Calamos Advisors

Calamos Advisors Portfolio holdings

AUM $28.2B
1-Year Est. Return 21.78%
This Fund
S&P 500
This Quarter Est. Return
+7.67%
1 Year Est. Return
+21.78%
3 Year Est. Return
+69.57%
5 Year Est. Return
+92%
10 Year Est. Return
+282.63%
AUM
$26.7B
AUM Growth
+$3.85B
Cap. Flow
-$4.59B
Cap. Flow %
-17.17%
Top 10 Hldgs %
20.41%
Holding
1,231
New
232
Increased
271
Reduced
149
Closed
114
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BIOSU
351
DELISTED
BioPlus Acquisition Corp. Unit
BIOSU
$10M 0.04%
+1,000,000
New +$10M
PRLHU
352
DELISTED
Pearl Holdings Acquisition Corp Unit
PRLHU
$10M 0.04%
+1,000,000
New +$9.99M
IPAXU
353
DELISTED
Inflection Point Acquisition Corp. Units
IPAXU
$9.97M 0.04%
1,000,000
TGAAU
354
DELISTED
Target Global Acquisition I Corp. Unit
TGAAU
$9.96M 0.04%
+1,000,000
New +$9.96M
SAIA icon
355
Saia
SAIA
$10.5B
$9.87M 0.04%
29,278
+7,262
+33% +$2.25M
OKLO
356
Oklo
OKLO
$6.41B
$9.85M 0.04%
1,000,000
ATVI
357
DELISTED
Activision Blizzard
ATVI
$9.85M 0.04%
148,051
+5,731
+4% +$392K
EL icon
358
Estee Lauder
EL
$30.4B
$9.81M 0.04%
26,499
-754
-3% -$256K
CTVA icon
359
Corteva
CTVA
$60.5B
$9.73M 0.04%
205,752
+7,965
+4% +$363K
MHK icon
360
Mohawk Industries
MHK
$6.91B
$9.69M 0.04%
53,188
+2,059
+4% +$367K
DRI icon
361
Darden Restaurants
DRI
$24.3B
$9.69M 0.04%
64,296
+2,572
+4% +$380K
AHRNU
362
DELISTED
Ahren Acquisition Corp Unit
AHRNU
$9.66M 0.04%
+963,772
New +$9.65M
HZNP
363
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$9.48M 0.04%
+88,000
New +$9.6M
NOK icon
364
Nokia
NOK
$46.9B
$9.45M 0.04%
1,520,000
K
365
DELISTED
Kellanova
K
$9.45M 0.04%
156,201
+6,047
+4% +$357K
REGN icon
366
Regeneron Pharmaceuticals
REGN
$72.9B
$9.44M 0.04%
14,942
+578
+4% +$355K
NUE icon
367
Nucor
NUE
$58.3B
$9.39M 0.04%
82,290
TRIS.U
368
DELISTED
Tristar Acquisition I Corp. Units, each consisting of one Class A Ordinary Share and one-half of one Redeemable Warrant to purchase one Class A Ordinary Share
TRIS.U
$9.27M 0.03%
+900,000
New +$8.99M
PGSS.U
369
DELISTED
Pegasus Digital Mobility Acquisition Corp. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant
PGSS.U
$9.26M 0.03%
+918,300
New +$9.24M
MTB icon
370
M&T Bank
MTB
$36.3B
$9.24M 0.03%
60,140
+2,328
+4% +$357K
BWIN
371
Baldwin Insurance Group
BWIN
$2.75B
$9.23M 0.03%
255,584
+52,356
+26% +$1.93M
FE icon
372
FirstEnergy
FE
$28.4B
$9.17M 0.03%
220,472
+8,535
+4% +$329K
CX icon
373
Cemex
CX
$16.9B
$9.16M 0.03%
1,350,528
-722,515
-35% -$4.71M
INSP icon
374
Inspire Medical Systems
INSP
$1.47B
$9.08M 0.03%
39,449
+1,722
+5% +$420K
KHC icon
375
Kraft Heinz
KHC
$32.8B
$9.08M 0.03%
252,805
+9,787
+4% +$352K

Similar funds

Calamos Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Calamos Advisors held 1,231 positions worth $26.7B, up 17% from $22.9B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Calamos Advisors withdrew a net $4.59B in Q4 2021, closing 114 positions and reducing 149 holdings. Its most notable exit was AstraZeneca, an estimated $17.8M position sold in full.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Calamos Advisors opened a new position in Broadcom Inc. 8.00% Mandatory Convertible Preferred Stock, Series A worth $169M.

  • Calamos Advisors's largest Q4 2021 buy was Broadcom Inc. 8.00% Mandatory Convertible Preferred Stock, Series A: 81,590 shares worth $169M.
  • Calamos Advisors added most to State Street SPDR S&P 500 ETF Trust in Q4 2021, an estimated $151M increase.
  • Calamos Advisors's biggest Q4 2021 reduction was JPMorgan Chase, cutting an estimated $29.5M.
  • Calamos Advisors fully exited AstraZeneca in Q4 2021, selling an estimated $17.8M.
  • Calamos Advisors's ten largest holdings make up 20% of its $26.7B portfolio in Q4 2021.
  • Calamos Advisors opened 232 new positions and closed 114 in Q4 2021.
  • Calamos Advisors's portfolio value rose 17% quarter-over-quarter to $26.7B.

Based on Calamos Advisors's 13F filing for Q4 2021, filed 1 Feb 2022.